EUVIMEDEUVIMED entdecken
Crossref

Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer

Glenwood D Goss iD, Gail E Darling, Virginie Westeel iD, Kazuhiko Nakagawa iD, Bartomeu Massutí iD, Francesco Perrone iD, Sue-Anne McLachlan, Jin Hyoung Kang iD, Yi-Long Wu iD, Anne-Marie C Dingemans iD, Rafal Dziadziuszko iD, Laurent Greillier iD und 16 weitere

Journal of Clinical Oncology · 01.03.2026 · 44 (7) · 553-564

DOI: 10.1200/jco-25-01828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2026. Verfasst von Glenwood D Goss und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adjuvant immunotherapy improved patient outcomes in two trials in completely resected non–small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer Trials Group BR.31 trial evaluated adjuvant durvalumab in completely resected early-stage NSCLC. METHODS Following resection of stage IB (≥4 cm) to IIIA NSCLC (American Joint Committee on Cancer 7th Edition) and optional adjuvant chemotherapy, patients were randomly assigned 2:1 to durvalumab 20 mg/kg or placebo 20 mg/kg once every 4 weeks for 12 cycles. Random assignment was stratified by stage, extent of nodal dissection, tumor cell (TC) PD-L1 expression, adjuvant chemotherapy use, and center. The primary end point was investigator-assessed disease-free survival (DFS). Secondary outcomes included overall survival (OS), adverse events, and quality of life. The primary analysis was in the subgroup with cancers that had a PD-L1 TC expression ≥25%, no common activating EGFR mutations ( EGFR –), and no ALK gene rearrangements ( ALK –). Secondary analyses in hierarchical order included DFS in the subgroup whose tumors were EGFR–/ALK– with PD-L1 TC ≥1%, followed by all patients whose tumors were EGFR–/ALK–, followed by OS in the same primary and secondary subgroups in the same hierarchical order. RESULTS Of 1,415 patients randomly assigned, 1,219 (86%) had EGFR–/ALK– tumors: 815 randomly assigned to durvalumab and 404 to placebo. With a median follow-up of 60 months, there were no differences in DFS between patients assigned durvalumab (316) versus placebo (161) in the primary population (stratified hazard ratio [HR], 0.93 [95% CI, 0.71 to 1.25]; P = .64) or in the secondary populations. Grade 3 to 4 adverse events were higher in durvalumab-treated patients (D = 26% v P = 20%). CONCLUSION Adjuvant durvalumab following complete resection was not associated with improvement in DFS compared with placebo in EGFR –/ ALK – NSCLC, regardless of PD-L1 status.

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada.
  • Department of Surgery Dalhousie University, Halifax, Canada.
  • Service de Pneumologie, Oncologie Thoracique et Allergologie Respiratoire, Centre Hospitalier Universitaire de Besançon, Besancon, France.
  • Kindai University Hospital Cancer Center, Osaka Sayama, Japan.
  • Medical Oncology Department, Alicante University, Dr Balmis Hospital, Alicante, Spain.
  • Unità Sperimentazioni Cliniche, Istituto Nazionale Tumori-IRCCS Fondazione Pascale, Napoli, Italy.

ORCID-Profile: Glenwood D Goss, Virginie Westeel, Kazuhiko Nakagawa, Bartomeu Massutí, Francesco Perrone, Jin Hyoung Kang, Yi-Long Wu, Anne-Marie C Dingemans, Rafal Dziadziuszko, Laurent Greillier, Shunichi Sugawara, Ernest Nadal, Annamaria Catino, Tetsuya Mitsudomi, Renaud Whittom, Manuel Domine, Nobuyuki Yamamoto, Olivier Molinier, Franck Morin, Martin R Stockler

Zitieren

APA

Goss, G. D., Darling, G. E., Westeel, V., Nakagawa, K., Massutí, B., Perrone, F., McLachlan, S. A., Kang, J. H., Wu, Y. L., Dingemans, A. C., Dziadziuszko, R., Greillier, L., Okada, M., Audigier-Valette, C., Sugawara, S., Nadal, E., Catino, A., Toffart, A. C., Mitsudomi, T., …, & O'Callaghan, C. J. (2026). Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer. Journal of Clinical Oncology, 44(7), 553-564. https://doi.org/10.1200/jco-25-01828

Vancouver

Goss GD, Darling GE, Westeel V, Nakagawa K, Massutí B, Perrone F, et al. Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 2026;44(7):553-564. doi:10.1200/jco-25-01828

BibTeX
@article{Goss2026,
  author = {Goss, Glenwood D and Darling, Gail E and Westeel, Virginie and Nakagawa, Kazuhiko and Massutí, Bartomeu and Perrone, Francesco and McLachlan, Sue-Anne and Kang, Jin Hyoung and Wu, Yi-Long and Dingemans, Anne-Marie C and Dziadziuszko, Rafal and Greillier, Laurent and Okada, Morihito and Audigier-Valette, Clarisse and Sugawara, Shunichi and Nadal, Ernest and Catino, Annamaria and Toffart, Anne-Claire and Mitsudomi, Tetsuya and Whittom, Renaud and Domine, Manuel and Yamamoto, Nobuyuki and Molinier, Olivier and Morin, Franck and Bradbury, Penelope A and Stockler, Martin R and Ding, Keyue and O'Callaghan, Christopher J},
  title = {Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {7},
  pages = {553--564},
  doi = {10.1200/jco-25-01828}
}
Kostenlos starten →